NV and Thyroid Function in the 2 Subgroups at the 12th Month
| Characteristic | Subgroup A: 11 subjects (RAI) | Subgroup B: 11 subjects (PEI + RAI) |
|---|---|---|
| Nodule volume (mL) | 21.9 ± 12.3 (8.1–41.5) | 13.2 ± 12.9 (1.2–49.3) |
| Percentage of NV reduction | 57.2 ± 16.3 (30.0–82.9) | 79.3 ± 14.7* (56.0–96.5) |
| SYS | 2.3 ± 0.6 (1–4) | 1.4 ± 0.3* (0–4) |
| FT4 (pmol/L) | 12.7 ± 2.7 (8.6–18.3) | 14.5 ± 1.9 (12.4–19.2) |
| FT3 (pmol/L) | 4.4 ± 0.9 (3.0–5.9) | 4.2 ± 0.7 (3.1–5.7) |
| TSH (mU/L) | 3.64 ± 5.52 (0.01–18.4) | 1.9 ± 1.2 (0.2–4.2) |
↵* P < 0.01 vs. group A.
Data are given as mean ± SD, with range in parentheses. Normal ranges were 9–24.5 pmol/L for FT4, 2.9–6.5 pmol/L for FT3, and 0.2–4 mU/L for TSH. SYS includes pressure symptoms in neck, dysphagia, and aesthetic complaints. Percentage of NV reduction is calculated as NV (mL) 12 mo after treatment/NV (mL) at baseline × 100.